Clinical Trial Update: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update for HiFiBiO's HFB200301 as a single agent and in combination with tislelizumab in adults with advanced solid tumors, acr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Mesothelioma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Sarcoma
• Testicular Germ Cell Tumor

Drugs mentioned

• HFB200301
• TIVDAK (tisotumab vedotin)

Snippet

Sponsor: HiFiBiO Therapeutics | Conditions: Gastric Cancer, Renal Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING